Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by Snowballgrowthon May 02, 2020 11:44am

130 Views

Post# 30979360

RE:RE:RE:RE:RE:RE:RE:Remdesivir get approved for emergency use for Covid-19

MUGMODs wrote: I absolutely agree with you Snowballgrowth.
That's why I asked the last question in my message, "but who ?" as it may not be Knight.

But ...

As Knight gets bigger and covers more geographies (unlike Paladin), it becomes harder to ignore them as a potential partner.

Maybe not Gilead ... but the opportunities will come (IMO).

I have very low expectations about futur big drugs. I think Goodman wouldn't pay a high price. So there is more probability for a deal about large pharmas trash

Bullboard Posts

Eminent acquires promising Nevada gold project